Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Status: Completed

Protocol number: NO16006

Sponsor: Hoffmann-La Roche Inc

Company division: Pharmaceutical

Official Scientific Title: A randomized, open-label study of the effect of PEGASYS versus Roferon-A on cytogenetic response in patients with chronic myelogenous leukemia

Brief summary: This study will evaluate the safety and efficacy of PEGASYS compared with Roferon-A in patients with recently diagnosed chronic phase myelogenous leukemia who have not received prior interferon therapy. The anticipated time on study treatment is 12 months or until progressive disease and the target sample size is 500+ individuals. Target sample size is 145.

Study phase: III

Study type: Interventional; Treatment; Randomized; Open Label; Active; Parallel; Safety/Efficacy study

Condition: Myelogenous Leukemia, Chronic

Intervention type: Drug

Intervention name: peginterferon alfa-2a (40KD)[PEGASYS]

Primary outcome: 1. Efficacy: Major cytogenetic response based on karyotypic analysis, and complete hematologic response, at 12 months

Key secondary outcomes: 1. Safety: Adverse events, laboratory tests results, vital signs, survival rate at 2 years

Inclusion criteria:

  • adult patients >=18 years of age;
  • confirmed chronic phase myelogenous leukemia diagnosed within 12 months before start of study.

Exclusion criteria:

  • previous interferon therapy or treatment with any investigational agents;
  • fertile men or women unless surgically sterile or using adequate contraceptive methods, and pregnant or lactating women;
  • candidates for bone marrow transplant within the next 6 months.

Gender: Males or Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Trial registration date: 07/26/2005

Date last updated: 8/19/2008


Link to trial result

This trial was conducted at the following locations:

Austria

  • Graz
  • Wien

Bulgaria

  • Pleven
  • Sofia
  • Varna

Canada

  • Halifax, NS
  • London, ON
  • Ottawa, ON
  • Toronto, ON

China

  • Hong Kong

Czech Republic

  • Olomouc
  • Praha

France

  • Lille
  • Lyon
  • Paris
  • Pessac
  • Poitiers
  • Strasbourg

Germany

  • Hannover
  • Mainz
  • Mannheim
  • Tübingen

Hungary

  • Budapest

India

  • Ahmedabad
  • Hyderabad
  • Lucknow
  • Trivandrum

Israel

  • Haifa
  • Rehovot

Italy

  • Bari
  • Bologna
  • Pavia
  • Pisa
  • Roma
  • Torrette di Ancona
  • Udine

Mexico

  • Monterrey

Poland

  • Warszawa

Russian Federation

  • Moscow
  • St Petersburg

Slovakia

  • Banska Bystrica
  • Bratislava
  • Kosice

South Africa

  • Cape Town
  • Durban
  • Johannesburg

Spain

  • Madrid
  • Toledo
  • Zaragoza

Taiwan

  • Taipei

Thailand

  • Bangkok

United Kingdom

  • London

United States

  • Phoenix, AZ
  • Los Angeles, CA
  • Santa Rosa, CA
  • Wilmington, DE
  • New Orleans, LA
  • New York, NY
  • Stony Brook, NY
  • Memphis , TN

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply